Overview

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Status:
NOT_YET_RECRUITING

Trial end date:
2031-10-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

BioNTech SE

Treatments:

atezolizumab
Bevacizumab
Ipilimumab